WuXi AppTec Co. Ltd. Buys New Shares in Adagene Inc. (NASDAQ:ADAG)

WuXi AppTec Co. Ltd. acquired a new position in shares of Adagene Inc. (NASDAQ:ADAG) during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 4,225,696 shares of the company’s stock, valued at approximately $8,162,000. Adagene accounts for about 21.2% of WuXi AppTec Co. Ltd.’s investment portfolio, making the stock its 3rd biggest holding. WuXi AppTec Co. Ltd. owned 0.10% of Adagene as of its most recent filing with the Securities and Exchange Commission.

Adagene Stock Performance

Shares of ADAG stock traded down $0.06 during mid-day trading on Wednesday, reaching $2.19. The company’s stock had a trading volume of 197,731 shares, compared to its average volume of 84,472. The company has a current ratio of 3.61, a quick ratio of 3.61 and a debt-to-equity ratio of 0.19. The firm’s 50-day moving average is $2.74 and its two-hundred day moving average is $2.45. Adagene Inc. has a 1-year low of $1.10 and a 1-year high of $4.38.

Adagene Company Profile

Adagene Inc, a clinical stage immunotherapy company, engages in the research, development, and production of monoclonal antibody drugs for cancers. The company's product candidates include ADG106, a human ligand-blocking agonistic anti- CD137 IgG4 monoclonal antibodies (mAbs) that is in Phase 1b/2 clinical trials for the treatment advanced solid tumors and non-Hodgkin's lymphoma; ADG126, a fully-human anti-CTLA-4 mAb that is in Phase 1 clinical trial for the treatment advanced/metastatic solid tumors; and ADG116, a human ligand-blocking anti-CTLA-4 mAb, which is in Phase I clinical trial for the treatment of advanced metastatic solid tumors.